Antihypertensive efficacy of losartan vs olmesartan
Pro Research Analysisby 
Searched over 200M research papers
Comparative Antihypertensive Efficacy: Olmesartan vs Losartan
Blood Pressure Reduction: Diastolic and Systolic Outcomes
Multiple studies consistently show that olmesartan is more effective than losartan in reducing both diastolic and systolic blood pressure in patients with hypertension. In randomized, double-blind trials, olmesartan at a starting dose of 20 mg once daily produced a significantly greater reduction in sitting cuff diastolic blood pressure (DBP) compared to losartan 50 mg once daily. For example, one study reported a DBP reduction of 13.5 mm Hg with olmesartan versus 8.2 mm Hg with losartan, and a 24-hour mean DBP reduction of 8.5 mm Hg with olmesartan compared to 6.2 mm Hg with losartan. The reduction in systolic blood pressure (SBP) was also greater with olmesartan (12.5 mm Hg) than with losartan (9.0 mm Hg) over 24 hours, though differences in SBP were sometimes less pronounced than for DBP 1245+1 MORE.
Meta-Analyses and Network Reviews: Broader Evidence
Meta-analyses and network reviews further confirm these findings. A meta-analysis of 22 randomized controlled trials found that olmesartan provided greater reductions in both DBP and SBP compared to losartan, with no increase in adverse events. Another large network meta-analysis ranked olmesartan highest among six commonly used angiotensin II receptor blockers (ARBs) for reducing office systolic and diastolic blood pressure, and also found olmesartan to have a favorable safety profile. Losartan and valsartan were generally less effective than olmesartan in these analyses 910.
Efficacy in Different Patient Populations
Studies in various populations, including those with mild to moderate hypertension, have shown that olmesartan maintains its superior efficacy over losartan. In both short-term (8–12 weeks) and longer-term studies, olmesartan consistently achieved greater reductions in blood pressure. Some studies also noted that fewer patients on olmesartan required additional antihypertensive medications compared to those on losartan 57.
Safety and Tolerability
Both olmesartan and losartan are well tolerated, with low and similar rates of adverse events reported across studies. No significant differences in safety profiles were observed, and both drugs were considered safe for use in patients with hypertension 1256+3 MORE.
Additional Clinical Considerations
Some studies also compared the effects of olmesartan and losartan on metabolic parameters such as lipid profiles and blood glucose. While olmesartan was the most effective in reducing blood pressure, telmisartan (another ARB) showed the most favorable effects on fasting blood glucose and lipid profile, with losartan and olmesartan having similar efficacy in these secondary outcomes .
Conclusion
In summary, olmesartan demonstrates superior antihypertensive efficacy compared to losartan, particularly in reducing diastolic blood pressure, with a similar safety and tolerability profile. These findings are consistent across randomized controlled trials, meta-analyses, and network reviews, making olmesartan a more effective option for blood pressure control in patients with hypertension 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic